

23 March 2017

Omni Innovation - US Manufacturer Appointed

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on its portfolio company, Omni Innovation, the medical technology company focused on medical nutrition.

US Distribution

Omni Innovation has appointed Windmill Health Products, LLC based in New Jersey to manufacture Omni Innovation's US brand GlucoSmooth™ for distribution across the US. Windmill Health Products, LLC has over 40 years' experience as a contract manufacturer as well as manufacturing its own products and distributing to over 150,000 retailers both in the US and international markets. In the US, it is estimated that over 44m people, 12.9% of the population, have diabetes with a further 86m people thought to have pre-diabetes¹. The US diabetes health market expenditure in 2015 was reported to be US\$320b per year².

"We are very pleased to have secured the manufacturing services in the US of a highly reputable, capable, experienced manufacturer with extensive export capability as Windmill Health Products. This is the achievement of a significant milestone for our clinically proven type 2 diabetes and pre-diabetes product prior to its entry into the substantial US market" said Arie Nudel, Managing Director of Omni Innovation

Distribution in the US is planned to be a combination of direct sales and traditional pharmacy/healthcare retail outlets. The first production run is expected to commence within 4-6 weeks.

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments

About Omni Innovation

Omni Innovation is a private Melbourne based medical nutrition company. Omni Innovation have, and continue to develop clinically validated and evidence-based dietary interventions in the areas of type-2 diabetes, pre-diabetes, medical weight management to improve health and quality of life.

Omni Innovation's pre-meal drink for the dietary management of type 2 diabetes and pre-diabetes is available under licence in Australia from Symbion Ltd (EBOS Ltd) under the Faulding® GlucoControl™ brand. From July 2017, the Company's pre-meal drink will be available to UK customers through Healthspan.

For more information, please visit www.omniinnovation.com.au

¹ <https://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf>

² <http://www.diabetesatlas.org/>